Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)

Trial Profile

Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PROMETEO

Most Recent Events

  • 27 Sep 2022 Planned End Date changed from 1 Nov 2023 to 27 Apr 2025.
  • 01 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.
  • 01 Apr 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top